Your browser doesn't support javascript.
loading
Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.
Erbe, Amy K; Wang, Wei; Carmichael, Lakeesha; Hoefges, Anna; Grzywacz, Bartosz; Reville, Patrick K; Ranheim, Erik A; Hank, Jacquelyn A; Kim, KyungMann; Seo, Songwon; Mendonca, Eneida A; Song, Yiqiang; Kenkre, Vaishalee P; Hong, Fangxin; Gascoyne, Randy D; Paietta, Elisabeth; Horning, Sandra J; Miller, Jeffrey S; Kahl, Brad; Sondel, Paul M.
Afiliación
  • Erbe AK; Department of Human Oncology, University of Wisconsin, Madison, WI, USA.
  • Wang W; Department of Human Oncology, University of Wisconsin, Madison, WI, USA.
  • Carmichael L; Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA.
  • Hoefges A; Department of Human Oncology, University of Wisconsin, Madison, WI, USA.
  • Grzywacz B; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
  • Reville PK; Department of Human Oncology, University of Wisconsin, Madison, WI, USA.
  • Ranheim EA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
  • Hank JA; Department of Human Oncology, University of Wisconsin, Madison, WI, USA.
  • Kim K; Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA.
  • Seo S; Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA.
  • Mendonca EA; Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA.
  • Song Y; Department of Pediatrics, University of Wisconsin, Madison, WI, USA.
  • Kenkre VP; Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA.
  • Hong F; Department of Medicine, University of Wisconsin, Madison, WI, USA.
  • Gascoyne RD; Department of Biostatistics, Harvard University, Dana Farber Cancer Institute, Boston, MA, USA.
  • Paietta E; Department of Pathology and Laboratory Medicine, Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
  • Horning SJ; Montefiore Medical Center-North Division, Albert Einstein College of Medicine, Bronx, NY, USA.
  • Miller JS; Department of Medicine, Stanford University, Stanford, CA, USA.
  • Kahl B; Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
  • Sondel PM; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
J Immunother Cancer ; 7(1): 70, 2019 03 12.
Article en En | MEDLINE | ID: mdl-30871628
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Antígenos HLA-B / Antígenos HLA-C / Linfoma Folicular / Receptores KIR2DL2 / Receptores KIR3DL1 / Rituximab Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: J Immunother Cancer Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Antígenos HLA-B / Antígenos HLA-C / Linfoma Folicular / Receptores KIR2DL2 / Receptores KIR3DL1 / Rituximab Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: J Immunother Cancer Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos